GlassScriptPhysician profile
Carol A Dobrzynski
NPI 1255407367
$9,759.51
in general payments reported to CMS, 2019-2025
32 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $1,233 · 2021: $1,426 · 2022: $1,478 · 2023: $1,377 · 2024: $1,512 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Education: $67.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.75 |
| Education | $67.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,998.99 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $997.94 | 2019-2025 | Rexulti |
| Abbvie INC. | $968.92 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $858.53 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $689.80 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $623.60 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $460.33 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $380.82 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $380.49 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $283.89 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $265.19 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Janssen Pharmaceuticals, INC | $204.60 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $196.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $193.91 | 2019-2023 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $149.17 | 2025 | Jornay Pm |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $124.70 | 2020-2022 | |
| Corium, LLC | $124.42 | 2024-2025 | Azstarys |
| Alkermes, INC. | $93.42 | 2025 | Aristada, Lybalvi |
| Harmony Biosciences LLC | $92.04 | 2021-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $82.65 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $79.26 | 2019-2022 | |
| Almatica Pharma LLC | $70.50 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Shire North American Group INC | $68.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $67.87 | 2019-2021 | |
| Lundbeck LLC | $59.44 | 2019-2022 | |
| Owp Pharmaceuticals, INC. | $58.97 | 2021-2025 | Subvenite, Lamotrigine |
| Adlon Therapeutics L.P. | $53.81 | 2019-2021 | |
| Noven Therapeutics, LLC | $47.28 | 2024 | Xelstrym |
| Rhodes Pharmaceuticals L.P. | $37.01 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.55 | 2019 | |
| Merck Sharp & Dohme LLC | $12.43 | 2022 | |
| Neurocrine Biosciences, INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Dobrzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.